Vascular endothelial cells play an important role in modulating cardiovascular function, by liberating several vasoactive substances, such as prostacyclin, endothelium-derived relaxing factor/nitric oxide, a hyperpolarizing substance, and vasoconstrictor substances. Their roles in the cardiovascular system include modulation of the contraction of the underlying vascular smooth muscle, interaction between blood components and blood vessel wall, vascular growth, as well as regulation of the cardiovascular system at several levels beyondthe vascular wall. Alterations in the endothelial functions and the related processes are nowknown to be involved in the pathogenesis of many cardiovascular diseases, including hypertension and atherosclerosis. Thus, the impaired endothelial regulation of the cardiovascular system may have an important implication for the development and progression of manycardiovascular diseases. (Internal Medicine 34: 939-946, 1995) 
Introduction
The endothelium is a monolayer of squamous cells in direct contact with the blood. Due to this anatomical position, it is a primary target for injuries such as hypertension, hyperlipidemia, diabetes mellitus and ischemia ( l^T). Since the demonstration by Furchgott and Zawadzki of the obligatory role of the endothelium in the relaxation to acetylcholine in the isolated aorta of the rabbit (5), it has become obvious that the endothelium modulates the degree of contraction of the underlying vascular smooth muscle. It does so by liberating vasoactive substances, such as prostacyclin (6, 7), endothelium-derived relaxing factor (EDRF, 5), a hyperpolarizing substance (endothelium-derived hyperpolarizing factor, EDHF, 8-10), and several constrictor substances (endothelium-derived contracting factors, EDCFs, 1 1, 12) (Fig. 1) . It is now clear that the endothelium possesses a variety of modulatory functions beyond the modulation of vascular tone and that alterations in the endothelial functions and the related processes are involved in the pathogenesis of many cardiovascular diseases (4).
This review briefly summarizes the present concept on the endothelium-dependent regulation of the cardiovascular system, particularly, the physiological roles of the endothelium.
Endothelium-Dependent Modulation of Vascular Tone
Endothelium-dependent relaxation The notion that EDRFmay be nitric oxide (NO) was first proposed by Furchgott (13) and by Ignarro et al (14) independently in 1986 at the international symposium on the "Mechanism of Vasodilatation" (The monograph was published in 1988). In 1987, Palmer et al (15) and Ignarro et al (16) reported that the biologically active component of EDRFis identical to NO. In 1988, it was demonstrated that NOis synthetized from L-arginine by oxidation of the guanidine-nitrogen terminal of L-arginine in the endothelial cells (17) (18) (19) . It is, however, still unclear whether NOis secreted by endothelial cells as a free radical or is bound to a carrier molecule (R-NO, e.g. S-nitrosocysteine) that dissociates at the cell membrane of vascular smooth muscle (20, 21) .
The enzyme that catalyzes the formation of NOis NO synthase (NOS). It is now established that there are at least three isoforms of NOS, that is, neuronal NOS(nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) (22) ( nNOSis widely distributed throughout the body, not only in the brain but also in peripheral non-adrenergic and non-cholinergic (NANC)nerves (nitrergic nerves) innervating the esophagus, the gastrointestinal tract, and certain blood vessels (22) (Fig. 2) . In neurons of the brain, NOmediates synaptic plasticity and in NANC nerves NOis released as a neurotransmitter and causes vascular relaxation, counterbalancing the vasoconstriction produced by the sympathetic nervous system (23-25) (Fig. 2) . In contrast, eNOSis specific for endothelial cells (22) . eNOScan no longerbe considered as a "constitutive" enzyme, because the expression of eNOScan be up-regulated by shear forces (26) and down-regulated by cytokines (27) . Both nNOSand eNOS synthesize small amounts of NOunder physiological conditions (22). iNOScan be induced in macrophages and other cells (22) . When induced in macrophages, iNOS produces large amounts of NOthat account for the cytotoxicity of these cells. In septic shock, iNOS is markedly up-regulated (presumably in vascular smooth muscle) by endotoxin and cytokines, and releases large amounts of NO, causing vascular paralysis characteristic of septic shock. Indeed, iNOS can be induced in isolated vascular smooth muscle by interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a) (28, 29) , and L-arginine analogues are effective in controlling endotoxin-induced hypotension (30).
The signal transduction pathway from the membrane receptors to NOSis not fully understood. However, there are at least two different pathways involved in the synthesis ofEDRF/ NOby endothelial cells, pertussis toxin-sensitive and -insensitive pathways (31). The agonists whose signal is mediated by the pertussis toxin-sensitive pathway include serotonin, oc2-agonist, thrombin, and aggregating platelets, and those whose signal is mediated by the pertussis toxin-insensitive pathway include bradykinin and adenosine diphosphate (3 1). NOis a very lipophilic compoundand thus does not require Shimokawaet al a cell surface receptor to mediate its action on vascular smooth muscle. NOproduced by the endothelium diffuses into the underlying vascular smoothmuscleto mediate vascular relaxation by a cyclic GMP-dependent process (32) (Fig. 1 ). For the activation of guanylate cyclase by NO, heme is required (33). Without heme, NOhas little activity on soluble guanylate cyclase (33). Thus, the "receptor" for NOin vascular smooth muscle appears to be the hemecomponentof soluble guanylate cyclase. Several pharmacologic studies suggest the existence of more than one EDRF (34, 35). Indeed, not all endotheliumdependent relaxation can be prevented fully by inhibitors of the L-arginine-NO pathway (36). The most likely candidate as a second EDRF is EDHF (8-10) (Fig. 1) . EDHFis an as yet unidentified substance that hyperpolarizes vascular smooth muscle and causes its relaxation. EDHFhyperpolarizes the vascular smooth muscle by opening K+channels (37, 38) although the subtype of K+ channels involved remains unknown. The extent of the contribution ofEDHFto endotheliumdependent relaxation is varied, depending on the tissue studied and the endothelium-dependent vasodilator used (36). EDHF acts on vascular smooth muscle in cooperation with NO.
Endothelium-dependent relaxation may be more important in resistance vessels than in large conduit arteries and mayplay a significant role in the regulation of peripheral vascular resistance (39). However, since the chemical nature of EDRFis still unknown, it is difficult to assess its contribution to endotheliumdependent relaxation in vivo (36). Recently, it has been proposed that EDHFmight be a cytochrome P450-derived arachidonic acid metabolite (40). Although prostacyclin is a potent inhibitor of platelet aggregation and possesses some vasodilator properties (6, 7), the contribution of prostacyclin to endothelium-dependent relaxation usually is minor (3, 4, 39).
Endothelium-dependent contractions Endothelium-dependent contractions have been described in some blood vessels under various conditions (1-4) and may play a role in maintaining vascular tone. These responses include contractions in response to hypoxia, indomethacinsensitive endothelium-dependent contractions, and contractions to endothelin.
Endothelium-dependent facilitation of the hypoxia-induced contractions were initially proposed to be mediated by a diffusable contracting factor from the endothelium (4 1 ). However, it was subsequently reported that endothelium-dependent contraction to hypoxia in the canine coronary artery can be blocked whenthe activity of EDRF/NO is reduced in advance either by methylene blue or inhibitors of NOsynthesis from Larginine (42, 43) . It was also shown that contractions to hypoxia can be induced in preparations without endothelium by moderate concentrations of donors of NOor a stable analog of cyclic GMP(42). Thus, it is now considered that the endotheliumdependent contractions to hypoxia are mainly due to the reduced activity of EDRF/NOcaused by hypoxia rather than to the release of a diffusable contracting factor (4). In the human internal mammaryartery, hypoxia-induced endothelium-dependent contractions can be attenuated by indomethacin or L-NMMA, an inhibitor of NOsynthesis, and are abolished by a combination of both inhibitors (44). Thus, in human endothelium, two contracting components are involved during hypoxia; a product of cyclooxygenase and the reduced activity of EDRF/NO (44).
Regarding the cyclooxygenase-dependent, endotheliumdependent contractions, two mediators of cyclooxygenase origin have been identified, to date. In the canine basilar artery, superoxide anions generated by hydroperoxidase activity of the enzyme are the likely mediators of the contractions (45). In contrast, in the aorta of spontaneously hypertensive or diabetic rats, prostaglandin H2 is the most likely mediator of the contractions (46^-8). In addition, L-arginine analogs also cause indomethacin-sensitive, endothelium-dependent contractions, which are attributed to the release of prostaglandin H2from the endothelium (49).
Endothelin was isolated from cultured endothelial cells by Yanagisawa et al in 1988 (50 Holtz et al demonstrated that flow-induced dilatation is dependent on the endothelium both in vitro and in vivo and is not modified by indomethacin (57). These observations were subsequently confirmed by other investigators, both in vitro and in vivo, in a variety of arteries from different sources (4). The basal release of EDRF/NOis markedly increased by pulsatile flow in vitro (58). However, the exact signal transduction mechanism underlying the synthesis/release of EDRF/NO via an increased blood flow still remains to be determined. In addition, in certain arteries, the local generation of bradykinin induced by the shear forces, may contribute to flow-induced dilatation (59).
The intra-arterial application of L-NMMA in the forearm of normal subjects causes peripheral vascular constriction (60). Experimental studies have indicated that NOsignificantly contributes to the fundamental regulatory mechanismsof coronary circulation, such as reactive hyperemia (65 , 66), metabolic dilatation (67, 68), and autoregulation (69). In the presence of a proximal stenosis of the coronary artery, NOmay play a more important role in maintaining myocardial perfusion during exercise (70). Indeed, it is conceivable that the NOsystem and other regulatory mechanisms(such as adenosine and ATPsensitive K channels) can compensate for each other to maintain tissue per fusion (65 , 7 1 ). It has been recently demonstrated that endothelial vasodilator dysfunction of the coronary resistance vasculature is associated with myocardial ischemia during exercise in patients without hemodynamicallysignificant stenoses of the epicardial coronary artery (72). Thus, the release of EDRF/NO maybe of pivotal importance for the maintenance of coronary blood flow during increased demand, both in animals and humans.
Endothelium-Dependent Modulation of the Interaction between Platelets and the Blood Vessel Wall
One of the most important physiological roles of the endothelium is the modulation of the interaction between blood components, in particular, platelets and the blood vessel wall (1) (2) (3) (4) . This endothelial function includes release of EDRF/NO in response to aggregating platelets and inhibition of platelet aggregation and adhesion. Endothelium-dependent relaxation to aggregating platelets was first described by Cohen et al in 1983 (73) (Fig. 1) . This relaxation opposes the platelet-induced, direct contraction of the vascular smooth muscle (73) (Fig. 1) . These findings, together with the demonstration of flow-induced endotheliumdependent relaxation (57) have established the physiological roles of EDRF/NO. Endothelium-dependent relaxation evoked by aggregating platelets are due to the combination of the responses to the platelet-derived adenine nucleotides (ATP and ADP)and serotonin (2-A). Thrombin, which is formed during blood coagulation, also causes endothelium-dependent relaxation (1-4). In most of the species tested (dogs, pigs and humans), adenine nucleotides play a major role in the endothelium-dependent relaxation to aggregating platelets, while platelet-derived serotonin also contributes to the relaxation in the dog and pig (1-4, 74_76 (8 1). NOalso prevents leukocyte adherence probably due to its ability to inactivate superoxide anion (85).
Endothelium-Dependent Regulation of Vascular Growth
Removalof the endothelium leads to proliferation of the underlying smooth muscle cells (86, 87) . Indeed, the intact endothelium produces both promotors and inhibitors of growth in a balanced, coordinated manner (88) . The promotors include basic fibroblast growth factor, platelet-derived growth factor and possibly also endothelin (89) . The inhibitory factors include heparin/heparan sulfate proteoglycans, transforming growth factor-p, and most likely NO (90) . Elevation of cyclic GMPlevels in smooth muscle cells is a commonfinal mechanism of actions of nitrovasodilators, including NO (90) . Thus, EDRF/NO may help to inhibit growth of smooth muscle cells even atphysiological concentration (88, 91) . Activation of endothelial tyrosine kinases, which are critical components in the signal transduction of proliferative stimuli evoked by growth factors, elicits the release of NOfrom the endothelium (92) . This could be one of the endothelial defense mechanismsagainst vascular proliferation. In the intact blood vessel wall, most of the NOformed is of endothelial origin (60). However, once the endothelium has been damaged,exposure of smoothmuscle cells to cytokines and other stimulators of NOSinduction may have important consequences for the blood vessel. Indeed, induction of NO production in medial smoothmuscle cells after endothelial damage may help to suppress their proliferative responses even before the regrowth of endothelial cells (93) . Cultured smooth muscle cells can also be stimulated to express inducible NOS (94) and to produce large amounts of NOwhen exposed to cytokines (95) . The production of large amounts of NO may in part counteract the stimulation ofproliferation by cytokines and growth factors (96) . Thus, NOis a potential inhibitor of the Internal Medicine Vol. 34, No. 10 (October 1995) proliferation of smooth muscle cells (88, 96) .
Nitric Oxide and Circulatory Control
NOmay contribute to the regulation of cardiovascular function at several levels beyond the vascular wall (Fig. 2) , including the brain, the arterial baroreceptors, the heart, the kidney and the adrenal gland (Fig. 2) . Wheninhibitors of NOsynthesis are injected in the brain either into the cisterna magna, or directly into the nucleus tractus solitarius, sympathetic nerve activity is augmentedwith a resultant increase in arterial blood pressure and heart rate (97, 98) . These effects are inhibited by L-arginine (97, 98) . In contrast, when NOis injected directly into the brain, sympathetic nerve activity, blood pressure and heart rate all decrease concomitantly (99) . Thus, in the brain (most likely at the level of the nucleus tractus solitarius), NOmodulates the cardiovascular system by inhibiting sympathetic nerve activity (Fig. 2) . Stretch increases the activity of the arterial baroreceptors and stimulates the release of vasoactive factors from the endothelium (100). In the isolated canine carotid sinus (previously denuded of endothelial cells), the threshold pressure for baroreceptor activities is reduced by the addition of cultured endothelial cells, activated by either bradykinin or the calcium ionophore A23 1 87 ( 100) . During stepwise increases in intraluminal pressure, the baroreceptor activity (assessed from singlefiber recordings) is higher at each level of pressure under control conditions than after exposure to cultured endothelial cells. Thus, endothelial cells may release a factor (presumably NO) that suppresses baroreceptor activity (100) (Fig. 2) . In the rat atrium, chemical removal of the endocardiumand the endothelium with saponin augmentsthe basal release of atrial natriuretic peptide (ANP) (101) . A similar effect can be obtained with inhibitors of EDRF/NOsuch as oxyhemoglobin and methylene blue, suggesting that EDRF/NOreleased from the endocardium (and/or the endothelium of the coronary vasculature) inhibits the release of ANP. Endothelial cells possess receptors for ANPwhich, when activated, increase the production of cyclic GMP (102) . Thus, endocardial (endothelial) cells may play a role in the feedback loop controlling the secretion of ANP (Fig. 2) .
In the preglomerular arterioles of the kidney, endothelial cells andjuxtaglomerular cells are in close anatomical proximity. Since endothelial cells respond to an increase in flow by releasing EDRF/NO, the latter could modulate renin release. Indeed, EDRF/NOreleased from isolated blood vessels of the dog or from cultured porcine endothelial cells, reduces the production of renin in slices of canine kidneys (103) . In this sense, endothelial cells may act as an intrarenal baroreceptor (3) (Fig.2 ).
In the adrenal gland, EDRF/NOreleased from capillaries of the adrenal medulla, inhibits the release ofcatecholamines (60). In addition, EDRF/NOinhibits the release of norepinephrine from adrenergic nerves at least in some blood vessels (104, 105 19) Sakuma I, Stuehr DJ, Gross SS, Nathan C, Levi R. Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85: 8664, 1988.
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